Human paraoxonase 2

EXCLI Journal

Volumn 9, Issue , 2010, Pages 159-172

  Porntadavity, Sureerut ^a   Permpongpaiboon, Thinnakorn ^b   Sukketsiri, Wanida ^c  

^a MAHIDOL UNIVERSITY   (Thailand)

^b Faculty of Medical Technology   (Thailand)

^c CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Antioxidant; Atherosclerosis; Oxidative stress; Paraoxonase 2

Indexed keywords

ARYLDIALKYLPHOSPHATASE 2;

ARYLDIALKYLPHOSPHATASE 2 GENE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DNA POLYMORPHISM; ENZYME ACTIVITY; GENE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN POLYMORPHISM; REVIEW; UPREGULATION;

EID: 80455137099     PISSN: None     EISSN: 16112156     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Altenhöfer S, Witte I, Teiber JF, Wilgenbus P, Pautz A, Li H, et al. One enzyme, two functions: PON2 prevents mitochondrial superoxide formation and apoptosis independent from its lactonase activity. J Biol Chem 2010;285:24398-403.
2. Aviram M, Volkova N, Coleman R, Dreher M, Reddy MK, Ferreira D, et al. Pomegranate phenolics from the peels, arils, and flowers are antiatherogenic: studies in vivo in atherosclerotic apolipoprotein E-deficient (E0) mice and in vitro in cultured macrophages and lipoproteins. J Agric Food Chem 2008;56:1148-57.
3. Boesch-Saadatmandi C, Pospissil RT, Graeser AC, Canali R, Boomgaarden I, Doering F, et al. Effect of quercetin on paraoxopnase 2 levels in RAW264.7 macrophages and in human monocytes-role of quercetin metabolism. Int J Mol Sci 2009;10:4168-77.
4. Boright AP, Connelly PW, Brunt JH, Scherer SW, Tsui LC, Hegele RA. Genetic variation in paraoxonase-1 and paraoxonase-2 is associated with variation in plasma lipoproteins in Alberta Hutterites. Atherosclerosis 1998;139:131-6.
5. Busch CP, Ramdath DD, Ramsewak S, Hegele RA. Association of PON2 variation with birth weight in Trinidadian neonates of South Asian ancestry. Pharmacogenetics 1999;9:351-6.
6. Chen D, Hu Y, Chen C, Yang F, Fang Z, Wang L, et al. Polymorphisms of the paraoxonase gene and risk of preterm delivery. Epidemiology 2004;15:466-70.
7. Chen Q, Reis SE, Kammerer CM, McNamara DM, Holubkov R, Sharaf BL, et al. Association between the severity of angiographic coronary artery disease and paraoxonase gene polymorphisms in the National Heart, Lung, and Blood Institutesponsored Women's Ischemia Syndrome Evaluation (WISE) study. Am J Hum Genet 2003;72:13-22.
8. Chi DS, Liang WH, Ma J, Xia M, Hou MJ, Wang Q, et al. Study of the association between paraoxonase1 55 Met/Leu, paraoxonase2 148/Gly and manganese superoxide dismutase (MnDOD) 9 Ala/Val genetic polymorphisms and coronary heart disease. Zhonghua Xin Xue Guan Bing Za Zhi 2006:27:808-13.
9. Draganov DI, La Du BN. Pharmacogenetics of paraoxonases: a brief review. Naunyn Schmiedeberg's Arch Pharmacol 2004;369: 78-88.
10. Draganov DI, Teiber JE, Speelman A, Osawa Y, Sunahara R, La Du BN. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res 2005;46: 1239-47.
11. Forte TM, Subbanagounder G, Berliner JA, Blanche PJ, Clermont AO, Jia Z, et al. Altered activities of anti-atherogenic enzymes LCAT, paraoxonase, and platelet-activating factor acetylhydrolase in atherosclerosissusceptible mice. J Lipid Res 2002;43:477-85.
12. Fuhrman B, Khateeb J, Shiner M, Nitzan O, Karry R, Volkova N, et al. Urokinase plasminogen activator upregulates paraoxonase2 expression in macrophages via an NADPH oxidase-dependent mechanism. Arterioscler Thromb Vasc Biol 2008;28: 1361-7.
13. Fuhrman B, Gantman A, Khateeb J, Volkova N, Horke S, Kiyan J, et al. Urokinase activates macrophage PON2 gene transcription via the PI3K/ROS/MEK/SREBP-2 signalling cascade mediated by the PDGFRbeta. Cardiovasc Res 2009;84:145-54.
14. Guxens M, Tomás M, Elosua R, Aldasoro E, Segura A, Fiol M, et al. Association between paraoxonase-1 and paraoxonase-2 polymorphisms and the risk of acute myocardial infarction. Rev Esp Cardiol 2008; 61:269-75.
15. Hassett C, Richter RJ, Humbert R, Chapline C, Crabb JW, Omiecinski CJ, et al. Characterisation of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence. Biochemistry 1991;30:10141-9.
16. Hayek T, Kaplan M, Kerry R, Aviram M. Macrophage NADPH oxidase activation, impaired cholesterol fluxes, and increased cholesterol biosynthesis in diabetic mice: a stimulatory role for D-glucose. Atherosclerosis 2007;195:277-86.
17. Hegele RA, Connelly PW, Scherer SW, Hanley AJ, Harris SB, Tsui LC, et al. Paraoxonase-2 gene (PON2) G148 variant associated with elevated fasting plasma glucose in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997;82: 3373-7.
18. Hegele RA, Harris SB, Connelly PW, Hanley AJ, Tsui LC, Zinman B, et al. Genetic variation in paraoxonase-2 is associated with variation in plasma lipoproteins in Canadian Oji-Cree. Clin Genet 1998;54:394-9.
19. Horke S, Witte I, Wilgenbus P, Krüger M, Strand D, Förstermann U. Paraoxonase-2 reduces oxidative stress in vascular cells and decreases endoplasmic reticulum stressinduced caspase activation. Circulation 2007;115:2055-64.
20. Horke S, Witte I, Wilgenbus P, Altenhöfer S, Krüger M, Li H, et al. Protective effect of paraoxonase-2 against endoplasmic reticulum stress-induced apoptosis is lost upon disturbance of calcium homoeostasis. Biochem J 2008;416:395-405.
21. Imai Y, Morita H, Kurihara H, Sugiyama T, Kato N, Ebihara A, et al. Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases. Atherosclerosis 2000;149:435-42.
22. Inagaki Y, Mashima Y, Funayama T, Ohtake Y, Fuse N, Yasuda N, et al. Paraoxonase 1 gene polymorphisms influence clinical features of open-angle glaucoma. Graefes Arch Clin Exp Ophthalmol 2006;244:984-90.
23. Jalilian A, Javadi E, Akrami M, Fakhrzadeh H, Heshmat R, Rahmani M, et al. Association of Cys311Ser polymorphism of paraoxonase-2 gene with the risk of coronary artery disease. Arch Iranian Med 2008;11:544-9.
24. Janka Z, Juhász A, Rimanóczy AA, Boda K, Márki-Zay J, Kálmán J. Codon 311 (Cys Ser) polymorphism of paraoxonase-2 gene is associated with apolipoprotein E4 allele in both Alzheimer's and vascular dementias. Mol Psychiatry 2002;7:110-2.
25. Kao Y, Donaghue KC, Chan A, Bennetts BH, Knight J, Silink M. Paraoxonase gene cluster is a genetic marker for early microvascular complications in type 1 diabetes. Diabet Med 2002;19:212-5.
26. Karban A, Hartman C, Eliakim R, Waterman M, Nesher S, Barnett-Griness O, et al. Paraoxonase (PON)1 192R allele carriage is associated with reduced risk of inflammatory bowel disease. Dig Dis Sci 2007;52: 2707-15.
27. La Du BN. Structural and functional diversity of paraoxonase. Nat Med 1996;2:1186-7.
28. Lazaros L, Markoula S, Kyritsis A, Georgiou I. Paraoxonase gene polymorphisms and stroke severity. Eur J Neurol 2010;17: 757-9.
29. Leus FR, Zwart M, Kastelein JJ, Voorbij HA. PON2 gene variants are associated with clinical manifestations of cardiovascular disease in familial hypercholesterolemia patients. Atherosclerosis 2001;154:641-9.
30. Levy E, Trudel K, Bendayan M, Seidman E, Delvin E, Elchebly M, et al. Biological role, protein expression, subcellular localization, and oxidative stress response of paraoxonase 2 in the intestine of humans and rats. Am J Physiol Gastrointest Liver Physiol 2007;293:G1252-61.
31. Liang HY, Wu BY, Chen DF, Yang F, Hu HY, Chen L, et al. Association of CYP2E1 of PON2 311 polymorphisms in neonates with preterm. Yi Chuan Xue Bao 2002a;29: 847-53.
32. Liang HY, Wu BY, Chen DF, Yang F, Hu HY, Chen L, et al. Association of PON2 gene polymorphisms in neonates with preterm. Yi Chuan Xue Bao 2002b;24:515-8.
33. Lim JA, Kim SH. Transcriptional activation of an anti-oxidant mouse Pon2 gene by dexamethasone. BMB Rep 2009;42:421-6.
34. Mackness B, Durrington PN, Abuashia B, Boulton AJ, Mackness MI. Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy. Clin Sci (Lond) 2000;98:355-63.
35. Mackness B, McElduff P, Mackness MI. The paraoxonase-2-310 polymorphism is associated with the presence of microvascular complications in diabetes mellitus. J Intern Med 2005;258:363-8.
36. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 1996;7:69-76.
37. Marchegiani F, Spazzafumo L, Provinciali M, Cardelli M, Olivieri F, Franceschi C, et al. Paraoxonase2 C311S polymorphism and low levels of HDL contribute to a higher mortality risk after acute myocardial infarction in elderly patients. Mol Genet Metab 2009;98:314-8.
38. Martinelli N, Girelli D, Olivieri O, Stranieri C, Trabetti E, Pizzolo F, et al. Interaction between smoking and PON2 Ser311Cys polymorphism as a determinant of the risk of myocardial infarction. Eur J Clin Invest 2004;34:14-20.
39. McKeown-Eyssen G, Baines C, Cole D, Riley N, Tyndale RF, Marshall L, et al. Case-control study of genotypes in multiple chemical sensitivity: CYP2D6, NAT1, NAT2, PON1, PON2 and MTHFR. Int J Epidemiol 2004;33:971-8.
40. Meilin E, Aviram M, Hayek T. Paraoxonase 2 (PON2) decreases high glucose-induced macrophage triglycerides (TG) accumulation, via inhibition of NADPH-oxidase and DGAT1 activity: Studies in PON2-deficient mice. Atherosclerosis 2009;208:390-5.
41. Mochizuki H, Scherer SW, Xi T, Nickle DC, Majer M, Huizenga JJ, et al. Human PON2 gene at 7q21.3: cloning, multiple mRNA forms, and missense polymorphisms in the coding sequence. Gene 1998;213:149-57.
42. Ng CJ, Wadleigh DJ, Gangopadhyay A, Hama S, Grijalva VR, Navab M, et al. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem 2001;276:44444-9.
43. Ng CJ, Hama SY, Bourquard N, Navab M, Reddy ST. Adenovirus mediated expression of human paraoxonase 2 protects against the development of atherosclerosis in apolipoprotein E-deficient mice. Mol Genet Metab 2006a;89:368-73.
44. Ng CJ, Bourquard N, Grijalva V, Hama S, Shih DM, Navab M, et al. Paraoxonase-2 deficiency aggravates atherosclerosis in mice despite lower apolipoproteinBcontaining lipoproteins: anti-atherogenic role for paraoxonase-2. J Biol Chem 2006b;281:29491-500.
45. Oliveira SA, Mansur AP, Ribeiro CC, Ramires JA, Annichino-Bizzacchi JM. PON1 M/L55 mutation protects high-risk patients against coronary artery disease. Int J Cardiol 2004;94:73-7.
46. Pan JP, Lai ST, Chiang SC, Chou SC, Chiang AN. The risk of coronary artery disease in population of Taiwan is associated with Cys-Ser 311 polymorphism of human paraoxonase (PON)-2 gene. Zhonghua Yi Xue Za Zhi (Taipei) 2002;65:411-2.
47. Pasdar A, Ross-Adams H, Cumming A, Cheung J, Whalley L, St Clair D, et al. Paraoxonase gene polymorphisms and haplotype analysis in a stroke population. BMC Med Genet 2006;7:28.
48. Pinizzotto M, Castillo E, Fiaux M, Temler E, Gaillard RC, Ruiz J. Paraoxonase2 polymorphisms are associated with nephropathy in type II diabetes. Diabetologia 2001;44:104-7.
49. Precourt LP, Seidman E, Delvin E, Amre D, Deslandres C, Dominguez M, et al. Comparative expression analysis reveals differences in the regulation of intestinal paraoxonase family members. Int J Biochem Cell Biol 2009;41:1628-37.
50. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. The human serum paraoxonase/ arylesterase gene (PON1) is one member of a multigene family. Genomics 1996;33: 498-507.
51. Qin Q, Li YL, Zhao FM, Wang H, Li Y, Cui RZ, et al. Association of paraoxonase polymorphisms and serum homocysteine thiolactone complex with coronary heart disease. Zhonghua Xin Xue Guan Bing Za Zhi 2006;34:803-7.
52. Ranade K, Kirchgessner TG, Iakoubova OA, Devlin JJ, DelMonte T, Vishnupad P, et al. Evaluation of the paraoxonases as candidate genes for stroke: Gln192Arg polymorphism in the paraoxonase 1 gene is associated with increased risk of stroke. Stroke 2005;36:2346-50.
53. Robertson KS, Hawe E, Miller GJ, Talmud PJ, Humphries SE. Northwick Park Heart Study II. Human paraoxonase gene cluster polymorphisms as predictors of coronary heart disease risk in the prospective Northwick Park Heart Study II. Biochim Biophys Acta 2003;1639:203-12.
54. Rosenblat M, Draganov D, Watson CE, Bisgaier CL, La Du BN, Aviram M. Mouse macrophage paraoxonase 2 activity is increased whereas cellular paraoxonase 3 activity is decreased under oxidative stress. Arterioscler Thromb Vasc Biol 2003;23: 468-74.
55. Rosenblat M. Hayek T, Hussein K, Aviram M. Decreased macrophage paraoxonase 2 expression in patients with hypercholesterolemia is the result of their increased cellular cholesterol content: effect of atorvastatin therapy. Arterioscler Thromb Vasc Biol 2004;24:175-80.
56. Rosenblat M, Oren R, Aviram M. Lysophosphatidylcholine (LPC) attenuates macrophage-mediated oxidation of LDL. Biochem Biophys Res Commun 2006;344: 1271-7.
57. Rosenblat M, Coleman R, Reddy ST, Aviram M. Paraoxonase 2 attenuates macrophage triglyceride accumulation via inhibition of diacylglycerol acyltransferase 1 the rate limiting enzyme in triglycerides biosynthesis. J Lipid Res 2009;50:870-9.
58. Rothem L, Hartman C, Dahan A, Lachter J, Eliakim R, Shamir R. Paraoxonases are associated with intestinal inflammatory diseases and intracellularly localized to the endoplasmic reticulum. Free Radic Biol Med 2007;43:730-9.
59. Saeed M, Iqbal P, Yousuf FA, Perveen S, Shafiq M, Sajid J, et al. Interactions and associations of paraoxonase gene cluster polymorphisms with myocardial infarction in a Pakistani population. Clin Genet 2007; 71:238-47.
60. Sanghera DK, Aston CE, Saha N, Kamboh MI. DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am J Hum Genet 1998;62:36-44.
61. Shamir R, Hartman C, Karry R, Pavlotzky E, Eliakim R, Lachter J, et al. Paraoxonases (PONs) 1, 2, and 3 are expressed in human and mouse gastrointestinal tract and in Caco-2 cell line: selective secretion of PON1 and PON2. Free Radic Biol Med 2005;39:336-44.
62. Shi J, Zhang S, Tang M, Liu X, Li T, Han H, et al. Possible association between Cys311Ser polymorphism of paraoxonase 2 gene and late-onset Alzheimer's disease in Chinese. Mol Brain Res 2004;120:201-4.
63. Shih DM, Gu L, Hama S, Xia Y-R, Navab M, Fogelman AM, et al. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J Clin Invest 1996;97:1630-9.
64. Shih DM, Gu LY, Xia R, Navab M, Li W, Hama S, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998; 394:284-7.
65. Shin BS. Paraoxonase gene polymorphism in south-western Korean population. J Korean Med Sci 2009;24:561-6.
66. Shiner M, Fuhrman B, Aviram M. Paraoxonase 2 (PON2) expression is upregulated via a reduced-nicotinamideadenine-dinucleotide-phosphate (NADPH)-oxidase-dependent mechanism during monocytes differentiation into macrophages. Free Radic Biol Med 2004;37: 2052-63.
67. Shiner M, Fuhrman B, Aviram M. A biphasic U-shape effect of cellular oxidative stress on the macrophage anti-oxidant paraoxonase 2 (PON2) enzymatic activity. Biochem Biophys Res Commun 2006;349: 1094-9.
68. Shiner M, Fuhrman B, Aviram M. Macrophage paraoxonase 2 (PON2) expression is up-regulated by pomegranate juice phenolic anti-oxidants via PPAR gamma and AP-1 pathway activation. Atherosclerosis 2007a; 195:313-21.
69. Shiner M, Fuhrman B, Aviram M. Macrophage paraoxonase2 (PON2) expression is upregulated by unesterified cholesterol through activation of the phosphatidylinositol 3-kinase (PI3K) pathway. Biol Chem 2007b;388:1353-8.
70. Slowik A, Tomik B, Wolkow PP, Partyka D, Turaj W, Marecki MT, et al. Paraoxonase gene polymorphisms and sporadic ALS. Neurology 2006;67:766-70.
71. Slowik A, Wloch D, Szermer P, Wolkow P, Malecki M, Pera J, et al. Paraoxonase 2 gene C311S polymorphism is associated with a risk of large vessel disease stroke in a Polish population. Cerebrovasc Dis 2007; 23:395-400.
72. Su SY, Chen JH, Huang JF, Wang XL, Zhao JG, Shen Y, et al. Paraoxonase gene cluster variations associated with coronary heart disease in Chinese Han women. Chin Med J (Engl) 2005;118:1167-74.
73. Thameem F, He X, Voruganti VS, Nath SD, Fanti P, Blangero J, et al. Evaluation of polymorphisms in paraoxonase 2 (PON2) gene and their association with cardiovascular-renal disease risk in Mexican Americans. Kidney Blood Press Res 2009;32:200-4.
74. Valdmanis PN, Kabashi E, Dyck A, Hince P, Lee J, Dion P, et al. Association of paraoxonase gene cluster polymorphisms with ALS in France, Quebec, and Sweden. Neurology 2008;71:514-20.
75. Voron'ko OE, Iakunina N, Shestakova MV, Zotova EV, Chugunova EV, Shamkhalova M, et al. A search for association between the polymorphic markers of PON1 and PON2 genes and diabetic nephropathy in patients with type I diabetes mellitus. Genetika 2005;41:844-9.
76. Wang X, Fan Z, Huang J, Su S, Yu Q, Zhao J, et al. Extensive association analysis between polymorphisms of PON gene cluster with coronary heart disease in Chinese Han population. Arterioscler Thromb Vasc Biol 2003a;23:328-34.
77. Wang XY, Xue YM, Wen SJ, Zhang NL, Ji Z, Pan SY. The association of paraoxonase 2 gene C311S variant with ischemic stroke in Chinese type 2 diabetes mellitus patients. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2003b;20:215-9.
78. Wheeler JG, Keavney BD, Watkins H, Collins R, Danesh J. Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: metaanalysis of 43 studies. Lancet 2004;363: 689-95.
79. Wills AM, Cronin S, Slowik A, Kasperaviciute D, Van Es MA, Morahan JM, et al. A large-scale international metaanalysis of paraoxonase gene polymorphisms in sporadic ALS. Neurology 2009; 73:16-24.
80. Wu BY, Liang HY, Chen DF, Liu L, Yang F, Hu HY, et al. Associations of Rsa I polymorphism at the 5' flanking region of CYP2E1 and PON2 148 polymorphism in neonates with preterm delivery. Chuan Xue Bao 2003;30:577-83.
81. Xu HW, Yuan N, Zhao Z, Zhang L, Xia J, Zeng KM, et al. Study of the relationship between gene polymorphisms of paraoxonase 2 and stroke in a Chinese population. Cerebrovasc Dis 2008;25:87-94.
82. Yamada Y, Ando F, Niino N, Miki T, Shimokata H. Association of polymorphisms of paraoxonase 1 and 2 genes, alone or in combination, with bone mineral density in community-dwelling Japanese. J Hum Genet 2003;48:469-75.